Pharvaris N.V.(US:PHVS) Globenewswire·2026-03-02 11:50Core Insights - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases, particularly hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][12] Clinical Data and Efficacy - The Phase 3 RAPIDe-3 study demonstrated that deucrictibant achieved rapid and sustained symptom relief for HAE attacks, with a median time to onset of symptom relief of 1.28 hours compared to over 12 hours for placebo [3][6] - Deucrictibant met all primary and secondary efficacy endpoints, with 90.4% of treated attacks achieving symptom relief within 12 hours, and a median time to complete resolution of 11.95 hours versus over 48 hours for placebo [3][6] - The long-term safety and efficacy of deucrictibant were supported by the Phase 2 CHAPTER-1 study, showing a reduction in attack rate from 2.18 attacks per month to 0.12 attacks per month over approximately three years [5][7] Quality of Life Improvements - Treatment with deucrictibant resulted in clinically meaningful improvements in health-related quality of life (HRQoL) and higher treatment satisfaction for participants over the long term [8] Novel Biomarker Development - Pharvaris has developed a kinin biomarker assay to measure bradykinin levels in plasma, which may aid in the characterization and management of bradykinin-mediated angioedema [10] Product Development and Regulatory Status - Deucrictibant is being developed in two formulations: an immediate-release capsule for on-demand treatment and an extended-release tablet for prophylactic use [11] - The company is preparing marketing authorization applications for the immediate-release capsule and is conducting a global pivotal Phase 3 study for the extended-release tablet, with topline data expected in Q3 2026 [12]